Dietary supplement beverages and functional nutrition
Strategic Profile
The company's brands are manufactured in the United States and distributed through major national retailers and leading online marketplaces. The company operates primarily in North America, with distribution through Amazon, diabetic sections of the nation's two largest pharmacy chains and other retail channels; revenues approach $1.1 million in recent fiscal years with gross margins above 40%. Since 2019, a core group of investors has made cumulative direct investments approaching $2 million, enabling the company to establish two trademarked soluble fiber-based nutrition brands with commercial traction and shelf placement in the diabetic sections of the nation's two largest pharmacy retailers.
Cyborg Score Rationale
Glucose Health demonstrates operational discipline with positive gross margins (40%+) and validated product formulations, but faces significant headwinds as a micro-cap OTC stock with minimal revenue (~$1.1M) and limited analyst coverage. Recent management transitions (October 2025) and debt elimination (January 2026) signal recovery, but execution risk remains high at this early stage.
Top Insights
(January 2026) Achieved debt-free balance sheet after settling $225,000 note via equity conversion with board member Edmund Burke
(October 2025) Appointed experienced small-cap CEO Mark Schaftlein and CFO/COO Marc Hatch with committed capital backing
(July 2025) Launched media campaign highlighting U.S. HHS designation of dietary fiber as nutrient of public health concern, validating patent-pending formulation
Patent-pending soluble-fiber formulations compete with major brands (Glucerna, Boost, Metamucil) across diabetic and wellness segments with estimated 2-in-5 adult Americans at pre-diabetes risk
Named Competitors
Glucerna — Diabetic nutrition beverages
Boost — Nutritional beverages and supplement drinks
Metamucil — Soluble fiber and digestive health products
Recent Developments
(January 2026) Completed debt-free balance sheet with conversion of $225,000 principal debt into 1.8M restricted common shares
(October 2025) Appointed Mark Schaftlein as CEO and Marc Hatch as CFO/COO; Christopher Jemapete joined board as strategic investor
(July 2025) Announced HHS designation of four nutrients of public health concern validating patent-pending fiber formulations; launched $XXM media blitz on CNBC, Fox Business, Bloomberg
(June 2025) Announced completion of preferred stock conversion at 85% premium to market, strengthening capital structure
Open the full interactive Glucose Health, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.